Vitamin D

One of the cheapest tests in the supplement aisle and the most useful: a meaningful share of adults in higher latitudes runs below the threshold where bone, immune, and possibly cardiovascular function start to wobble, and a low-cost lab plus a cheap pill closes that gap. But the trial evidence for routinely taking vitamin D when you're already replete is much thinner than the marketing implies.

For decades, observational studies linked low 25-hydroxyvitamin D to almost everything — heart disease, cancer, infections, depression, autoimmune conditions. The randomized trials that followed have been more measured: they confirm the importance of correcting genuine deficiency, but do not support routine supplementation in already-replete adults for primary cardiovascular or cancer prevention. The interesting exceptions are a handful of long-tail and subgroup findings — autoimmune disease, late-window cancer mortality, and biological aging — where the signal is real but the effect size is modest.

The headline evidence

Evidence: Strong for correcting deficiency; Weak for outcomes in the already-replete. The large randomized trials are null on their primary endpoints; the useful signals are subgroup and long-tail findings.

The largest randomized trial of vitamin D in adults is ^[1]. The primary endpoints — invasive cancer and major cardiovascular events — were null.

Three pre-specified or exploratory analyses pointed in a more useful direction:

Cancer mortality. VITAL's total cancer-death result was non-significant overall — a hazard ratio (HR) of 0.83, with a 95% confidence interval of 0.67–1.02. (Throughout this article, the bracketed range is where the true effect most plausibly lies; when it crosses 1.0, as here, the result is statistically compatible with no effect.) Excluding the first two years cut cancer deaths by about a quarter (HR 0.75, 95% CI 0.59–0.96) — but that latency analysis was not pre-specified, carried no multiple-comparison adjustment, and is best read as hypothesis-generating.^[2] The more defensible figure comes from a later individual-patient-data meta-analysis: daily D3 cut cancer mortality by about 12% (RR 0.88, 95% CI 0.78–0.98), while intermittent high-dose bolus regimens showed no benefit and the pooled all-trials estimate was null once the bolus-dosing D-Health trial was included (RR 0.94, 95% CI 0.86–1.02). Steady levels, not total dose, appear to matter.^[3]
Incident autoimmune disease fell by 22% over 5 years.^[4] This is the strongest randomized signal vitamin D has produced outside of bone.
Biological aging slowed on two markers vitamin D researchers watch closely — telomere length and epigenetic clocks. This is the most intriguing extra-skeletal signal in the recent literature, and it gets its own section below.

The negative findings round out the picture, and for a longevity readership they are the calibration that matters most:

All-cause mortality did not budge. VITAL found death from any cause HR 0.99 (95% CI 0.87–1.12).^[5] The D-Health trial (21,315 older Australians, 60,000 IU monthly) was likewise null, with the point estimate fractionally above 1.0 (HR 1.04, 95% CI 0.93–1.18).^[6] Across trials, supplementation does not lower all-cause mortality in well-nourished, already-replete adults.
The corrected genetic evidence agrees. An influential 2021 Mendelian-randomization paper that suggested a causal mortality benefit in deficient people was retracted in 2024 after its statistical methods were found invalid, then republished with a reversed, null conclusion: across 500,962 individuals, genetically-predicted 25-hydroxyvitamin D showed no causal association with all-cause mortality, cardiovascular disease, or stroke at any level — including the deficient stratum.^[7] This is the cleanest counterweight to causal claims: low vitamin D is largely a marker of poor health — chronic illness, inactivity, obesity, less time outdoors — rather than a cause of it, which is why observational associations are strong while randomized and genetic evidence are flat.
Fracture risk in non-deficient adults was unaffected by 2000 IU/day in the VITAL Fractures analysis.^[8] Vitamin D matters for bone, but mainly via correcting deficiency, not via "more is better" in already-replete adults.
Cognitive decline, mood, and diabetes have not moved in major randomized trials in initially-replete adults — including the well-powered VITAL-DEP depression trial (18,353 adults, 2000 IU/day, no effect on incident or recurrent depression).^[9]

Vitamin D and biological aging

Evidence: Weak. Both signals rest on surrogate markers (telomere length, methylation clocks) measured in single substudies, one of them only marginally significant — intriguing, not established.

Two recent results moved vitamin D out of pure disease prevention and into the territory this site cares about most — the pace of aging itself.

Telomeres. Telomeres are the protective caps on chromosomes that shorten with each cell division; their attrition is a hallmark of aging. In the four-year VITAL Telomere sub-study (1,031 participants with leukocyte telomere length measured at baseline, year 2, and year 4), adults taking 2000 IU/day of D3 lost significantly less telomere length than those on placebo — attrition was 0.14 kilobases lower over four years (95% CI 0.007–0.27; p = 0.039), i.e. roughly 140 base pairs spared. Marine omega-3 at 1 g/day had no effect on telomere length in the same trial.^[10] That sits on top of a large observational literature: across about 185,000 people, higher 25-hydroxyvitamin D tracks with longer leukocyte telomeres, most steeply in those climbing out of deficiency.^[11]

Epigenetic clocks. DO-HEALTH missed all six of its pre-specified primary endpoints; the DNA-methylation-clock result is a post-hoc secondary finding, not a headline. With that caveat: combining vitamin D with omega-3 and exercise nudged methylation aging clocks in adults over 70 — individual effects were modest, and the three interventions stacked clearly on only one of the clocks (PhenoAge).^[12] Cross-sectional data echo the direction: lower 25-hydroxyvitamin D associates with an older biological age on the PhenoAge clock. But the relationship is not "more is always younger" — in men, levels above roughly 92 nmol/L were associated with a slight acceleration of epigenetic age, a U-shape that argues against chasing the highest tolerable number.^[13]

The honest caveat: telomere length and methylation clocks are surrogate markers, and these are single substudies. The VITAL telomere result is a real randomized finding but only marginally statistically significant (p = 0.039), given the slow overall attrition and the limits of telomere measurement; telomere length itself tracks clinical outcomes only weakly. Neither finding is the same as a demonstrated gain in healthy years — and both sit alongside the null mortality data above, not above it.

What "deficient" actually means

Evidence: Moderate. The deficiency cutoffs and the mortality-plateau target are consistent across cohort studies; where to aim above the deficiency threshold is where the guidelines genuinely disagree.

The most widely-used cutoffs:

25(OH)D level	Status	Action
<30 nmol/L (<12 ng/mL)	Deficient	Correct urgently
30–50 nmol/L (12–20 ng/mL)	Insufficient	Supplement
50–125 nmol/L (20–50 ng/mL)	Sufficient	Maintain
>125 nmol/L (>50 ng/mL)	High	Reduce or stop supplementation
>250 nmol/L (>100 ng/mL)	Toxic risk	Stop; investigate hypercalcemia

Severe deficiency (<30 nmol/L) is uncommon in healthy adults eating a mixed diet at lower latitudes. Suboptimal status — 30–75 nmol/L — is widespread at higher latitudes, especially through autumn and winter, and is the gap most supplementation actually addresses.

The "vitamin D deficiency epidemic" framing from the 2010s was somewhat overstated; large-scale severe deficiency is rare in adults who eat normally and get any sun exposure. But the trial evidence supports correcting any insufficiency more strongly than chasing the highest tolerable level — supplementing toward 75–125 nmol/L is the defensible target.

Where the guidelines split

The mortality data anchor the low end. In cohort studies, all-cause and cardiovascular mortality fall steeply as 25-hydroxyvitamin D climbs out of deficiency and then flatten — the curve is essentially level above roughly 65 nmol/L (26 ng/mL).^[14] Most of the survival benefit is in escaping the bottom, not in reaching the top. That leaves a genuine disagreement about how high to aim:

The conservative position. A 2024 clinical guideline advises healthy adults aged 19–74 against routine 25-hydroxyvitamin D testing and against empiric high-dose supplementation, backing only the standard 600 IU/day recommended dietary allowance (RDA) — on the grounds that randomized trials have not shown extra-skeletal benefit in already-replete people. The one age-specific nuance for a longevity audience: the same panel does suggest empiric supplementation (above the RDA, without testing) for adults 75 and over, where it may lower mortality risk — and recommends daily over intermittent high-dose regimens in anyone who supplements.^[15]
The optimization position. A longevity-oriented camp argues for targeting 100–150 nmol/L (40–60 ng/mL), pointing to the telomere, epigenetic, autoimmune, and cancer-progression signals that emerge above the deficiency threshold. A widely-shared 2025 conference abstract reported halved repeat heart attacks under titrated high-dose vitamin D, but it is unpublished, not peer-reviewed, and runs against the entire randomized cardiovascular record — VITAL found no effect on major cardiovascular events (HR 0.97, 95% CI 0.85–1.12), and no large trial has shown a cardiovascular benefit. Treat it as a curiosity, not evidence.^[16]

The defensible middle hasn't changed: correcting any insufficiency toward 75–125 nmol/L has the strongest evidence behind it. The case for climbing into the 100–150 range rests on surrogate markers and subgroup findings rather than hard randomized outcomes, and the male epigenetic U-shape is a standing reminder that higher is not reliably better.

Practical dosing

Test first — with a caveat. A single morning 25-hydroxyvitamin D draw in autumn or winter (the seasonal trough) gives the most useful read. Note that both the US Preventive Services Task Force (an "insufficient evidence" verdict on screening asymptomatic adults) and the Endocrine Society advise against routine testing, since correcting an asymptomatic low level hasn't changed hard outcomes in trials. Testing earns its keep mainly when you want to dose deliberately rather than guess — not as a population screen.
Replete adults at the seasonal trough: 1000–2000 IU/day usually maintains target year-round.
Insufficiency (30–50 nmol/L): 2000 IU/day for 12 weeks, then retest.
Deficiency (<30 nmol/L): 4000 IU/day for 8–12 weeks, retest, then drop to maintenance.
Always take with a fat-containing meal. Vitamin D is fat-soluble; absorption on an empty stomach is poor.
Re-test annually at the end of winter once your maintenance dose is set.
Magnesium is a minor note. The enzymes that convert vitamin D into its active hormone are magnesium-dependent, so in principle low magnesium could blunt the response — but the clinical evidence that magnesium repletion changes 25(OH)D response in non-deficient people is thin. Worth a glance only if your level isn't rising on a sensible dose. See Magnesium.

Forms and timing

D3 (cholecalciferol) is the right form for almost everyone. Beyond raising blood levels more reliably than D2 (ergocalciferol), D2 appears to accelerate the clearance of the body's own D3 — a meta-analysis of D2 trials found circulating 25-hydroxyvitamin D3 dropping even as total vitamin D rose.^[17] Choose D3.
Daily dosing beats weekly or monthly megadosing — the body handles steady-state vitamin D more cleanly than large boluses, and the largest intermittent-dose trials hint at outright harm. An annual 500,000 IU dose raised falls by 15% and fractures by 26% in older women, concentrated in the three months after each dose,^[18] and the monthly-bolus D-Health trial saw a non-significant excess of cancer deaths (HR 1.15, 95% CI 0.96–1.39) — the opposite direction from VITAL's daily dosing. Steady daily dosing is the safe default; large intermittent boluses are at best useless and at worst harmful.
A drop or softgel is fine. The vehicle (olive oil, medium-chain triglyceride oil) doesn't matter much as long as you take it with a meal.
Calcifediol (25-OH-D3) raises serum 25-hydroxyvitamin D faster than ordinary D3 and is worth knowing about for malabsorption or when rapid correction is needed; for routine use, plain D3 is still the default.

Sun is not a substitute in winter

Above about 35° latitude (most of Europe and the northern US), winter UVB (the ultraviolet-B wavelengths that trigger synthesis) is too low for the skin to make any vitamin D between roughly October and March. The half-life of 25-hydroxyvitamin D is several weeks; a summer of good sun cannot cover a high-latitude winter. Use oral D3 across the dark months. See Sun exposure for the broader picture, including the data that strict sun avoidance roughly doubles all-cause mortality in long-running cohorts.

Pair with K2 if you're targeting bone

Evidence: Weak (mechanistically plausible, no hard-outcome trial).

Vitamin D raises calcium absorption from the gut. Vitamin K2 (menaquinone-7, MK-7) activates the proteins that direct that calcium into bone matrix rather than soft tissue and arterial walls. The combination has more biological coherence than either alone — but no large trial has shown that D3+K2 reduces fractures or cardiovascular events versus D3 alone in healthy adults, so treat it as mechanistically plausible rather than proven.

If you want it, 90–180 µg/day of MK-7 alongside D3 is reasonable. Coordinate with a prescriber if you're on warfarin — vitamin K antagonises it. See Vitamin K2 for the full evidence picture and Bone density for the loading side.

Cautions

Doses above 4000 IU/day without monitoring can cause hypercalcemia (rare but real). Stop and check serum calcium and 25(OH)D if you've been megadosing.
Granuloma-forming diseases (sarcoidosis, some lymphomas, tuberculosis) can dysregulate vitamin D metabolism — work with a clinician.
High-dose calcium supplementation has its own risk profile; dietary calcium does not show the same cardiovascular signal as high-dose calcium supplements. See Supplements to avoid.
Clinically meaningful vitamin D toxicity is rare from supplementation alone but real with cumulative megadosing over years.